MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Thermo Fisher Scientific Total Assets 2011-2026 | TMO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110 B | 97.3 B | 98.7 B | 97.2 B | 95.1 B | 69.1 B | 58.4 B | 56.2 B | 56.7 B | 45.9 B | 40.9 B | 42.9 B | 31.9 B | 27.4 B | 26.8 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 110 B | 26.8 B | 63.7 B |
Quarterly Total Assets Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103 B | 101 B | 99 B | 100 B | 98.5 B | 97.1 B | 97.1 B | 94.1 B | 94.7 B | 97.2 B | 90.5 B | - | 92.7 B | 95.1 B | 73.6 B | 67.7 B | 65.9 B | 69.1 B | 69.1 B | 69.1 B | 69.1 B | 58.4 B | 58.4 B | 58.4 B | 58.4 B | 56.2 B | 56.2 B | 56.2 B | 56.2 B | 56.7 B | 56.7 B | 56.7 B | 56.7 B | 45.9 B | 45.9 B | 45.9 B | 45.9 B | 40.8 B | 40.8 B | 40.8 B | 40.8 B | 42.9 B | 42.9 B | 42.9 B | 42.9 B | 31.9 B | 31.9 B | 31.9 B | 31.9 B | 27.4 B | 27.4 B | 27.4 B | 27.4 B | 26.8 B | 26.8 B | 26.8 B | 26.8 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 103 B | 26.8 B | 58.8 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
10.7 B | $ 113.86 | -0.85 % | $ 34.6 B |  USA |
 |
Danaher Corporation
DHR
|
83.5 B | $ 190.59 | -0.8 % | $ 136 B | USA |
 |
DexCom
DXCM
|
6.34 B | $ 63.64 | 0.68 % | $ 24.8 B | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 16.32 | -0.61 % | $ 493 M | USA |
 |
Guardant Health
GH
|
2.01 B | $ 90.59 | 1.04 % | $ 11.4 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 107.81 | -1.66 % | $ 8.89 B |  Irlanda |
 |
Illumina
ILMN
|
6.3 B | $ 127.23 | -0.4 % | $ 20.2 B | USA |
 |
CareDx, Inc
CDNA
|
413 M | $ 17.63 | -1.07 % | $ 939 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 274.85 | 0.14 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
2.23 B | $ 75.68 | -0.28 % | $ 5.11 B | USA |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 493.63 | -0.48 % | $ 14.2 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 16.99 | 4.23 % | $ 176 M |  China |
 |
Myriad Genetics
MYGN
|
707 M | $ 4.62 | -1.07 % | $ 428 M | USA |
 |
Co-Diagnostics
CODX
|
24.7 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
NeoGenomics
NEO
|
1.36 B | $ 7.98 | -0.5 % | $ 1.02 B | USA |
 |
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | USA |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 9.93 | 3.82 % | $ 2.15 B | USA |
 |
Natera
NTRA
|
1.39 B | $ 207.69 | 1.38 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
National Research Corporation
NRC
|
135 M | $ 17.24 | -0.52 % | $ 386 M | USA |
 |
Pacific Biosciences of California
PACB
|
784 M | $ 1.4 | -1.76 % | $ 420 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Precipio
PRPO
|
21.3 M | $ 26.0 | 0.08 % | $ 41.7 M | USA |
 |
Personalis
PSNL
|
270 M | $ 6.21 | -5.57 % | $ 368 M | USA |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 167.8 | -0.25 % | $ 8.32 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Sotera Health Company
SHC
|
3.26 B | $ 14.86 | -0.1 % | $ 4.22 B | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 24.96 | 0.93 % | $ 693 M | USA |
 |
Soleno Therapeutics
SLNO
|
564 M | $ 52.25 | - | $ 2.66 B | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
142 M | $ 1.6 | -9.09 % | $ 106 M | USA |
|
Biodesix
BDSX
|
97.2 M | $ 14.71 | -4.21 % | $ 1.91 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 26.99 | -0.79 % | $ 20 B |  Niderland |
 |
Trinity Biotech plc
TRIB
|
103 M | $ 0.61 | -1.34 % | $ 61.9 M | Irlanda |
 |
VolitionRx Limited
VNRX
|
6.9 M | $ 0.17 | -0.89 % | $ 21.4 M |  Singapore |
 |
Waters Corporation
WAT
|
5.08 B | $ 301.9 | -0.72 % | $ 18 B | USA |
 |
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
16.1 M | $ 2.59 | - | $ 84.1 K | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.08 | -4.13 % | $ 4.78 M | USA |
 |
BioNano Genomics
BNGO
|
73.6 M | $ 1.14 | -1.3 % | $ 6.21 M | USA |
 |
Interpace Biosciences
IDXG
|
33.8 M | $ 2.02 | 2.54 % | $ 8.94 M | USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M |  Israel |
 |
Celcuity
CELC
|
467 M | $ 113.87 | -0.31 % | $ 5.32 B | USA |